With the continuous and rapid development of China's innovative drug industry, more and more pharmaceutical companies have begun to accelerate product commercialization to enhance their self-"hematopoietic" ability
.
From the current point of view, under the strength of many enterprises, domestic innovative pharmaceutical companies have begun to enter the intensive period of
commercialization.
Recently, Henlius released its performance report
for the first half of 2022.
During the reporting period, Henlius achieved operating income of 1.
2894 billion yuan, an increase of about 103.
5%
over the same period last year.
It is reported that the increase in revenue mainly comes from the sales revenue and licensing income brought about by the commercialization of a variety of products
.
Among them, the core product Hanquyou ® achieved domestic sales revenue of 800.
2 million yuan, an increase of about 178.
2%
over the same period last year.
The first biosimilar Hanlikang ® (rituximab) in the first half of 2022 the company based on the profit sharing arrangement agreed with Jiangsu Fosun to obtain sales revenue of 272.
1 million yuan, licensing income of 9.
3 million yuan
.
According to the semi-annual report, in terms of product commercialization, Henlius's performance has actually been very eye-catching, and has now listed 5 products in China, and has also set up a commercialization team
of more than 800 people for core tumor and immunotherapy products.
In the first half of 2022, the company's biosimilar Hanquyou ® (trastuzumab) achieved domestic sales revenue of about RMB800.
2 million, an increase of about 178.
2%
over the same period last year.
Overseas sales revenue is approximately RMB12.
5 million and overseas licensing revenue is approximately RMB2.
4 million, based on the partnership
with Acoord.
Up to now, Hanquyou ® has been approved for listing
in more than 30 countries such as China, the United Kingdom, France, Germany, Switzerland and Australia.
According to the data, the revenue of Yasheng Pharmaceutical in 2021 increased by 123.
2% year-on-year to 27.
91 million yuan, mainly from the sales of the first commercial product, commercial licensing fee income and intellectual property licensing fee income
.
It is worth mentioning that from the approval of Nelik ® for listing, as of the end of February 2022, the cumulative invoice amount of the product is 50.
41 million yuan
.
In 2021, Yasheng Pharmaceutical's innovation investment continued to increase, and the annual R&D expenditure was RMB767 million, an increase of 35.
8%
over the same period last year.
It is understood that Yasheng Pharmaceutical has also set up a commercialization team with rich experience in the field of hematology and tumors, and has in-depth cooperation with Innovent Biologics to jointly promote the commercialization
of Nelik in China.
In 2021, Yasheng Pharmaceutical is actively laying out and establishing strategic cooperative relations with supply chain service providers represented by Sinopharm Holdings, Shanghai Pharmaceutical Holdings and China Resources Pharmaceutical to promote the commercialization process and accessibility
of Nelik in multiple dimensions.
The strength of Huadong Pharmaceutical in product commercialization should not be underestimated, and its commercialization and antidiabetic drug products under development have reached more than 20 models
.
Both from the number of product reserves and the target coverage field have a dominant position in the industry, and the product pipeline layout has reached the international advanced level
.
As a result, its products and commercialization capabilities are also gaining international recognition
.
In September 2021, Huadong Pharmaceutical successfully licensed TTP273, a global innovative GLP-1 oral small molecule product under research, to South Korea for a total amount of UP to US$
39 million.
Subsequently, in October 2021, Huadong Pharmaceutical also reached a strategic cooperation
with Takeda Pharmaceutical of Japan on the regional commercialization rights and interests of alogretine benzoate tablets in China.
According to the minutes of the investor activities of East China Pharmaceutical on April 28, nixina (agglitine benzoate tablets) has been selling well in the market promotion process this year, showing a good growth trend, and with the subsequent improvement of the epidemic, Nixina is expected to further increase the volume and complete the established sales targets
this year.
From the overall point of view, the current Chinese innovative drug industry has entered a mature stage of commercial competition, of which the biotech companies that have entered the market are striving to achieve transformation through successful commercialization of products; The big pharma/biopharma, which has a commercial variety, has cultivated a certain scale of sales and marketing teams
.
In this regard, analysts said that China's innovative drug industry has just started, there are bound to be weak links, so for a long time in the future, through License-in or License-out is expected to be an important step
to accelerate the commercialization of pharmaceutical products.
